Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Associated Scientists to Help Minimize Allergies Janssen Pharmaceuticals Eisai Medical Research Inc. |
---|---|
Information provided by: | Associated Scientists to Help Minimize Allergies |
ClinicalTrials.gov Identifier: | NCT00214552 |
The hypothesis for this study is that potent anti-secretory therapy with high dose PPI improves asthma control regardless of either asthma severity or the presence of GERD symptoms.
Condition | Intervention | Phase |
---|---|---|
Asthma Gastroesophageal Reflux Disease |
Drug: rabeprazole |
Phase III |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment |
Official Title: | A Double-Blind Placebo Controlled Clinical Trial to Evaluate the Effects on Asthma Control of Rabeprazole Given Twice Daily in Subjects With Asthma. |
Estimated Enrollment: | 80 |
Study Start Date: | September 2002 |
Estimated Study Completion Date: | March 2005 |
Many patients with GERD do not experience heartburn symptoms. Barium esophagram, endoscopy and/or overnight esophageal pH monitoring are commonly relied upon to objectively establish the diagnosis of GERD. In general, overnight esophageal pH monitoring is the most sensitive and specific test available to confirm GERD. However, the literature exploring GERD as a cause of chronic cough suggests that the currently accepted criteria for defining abnormal overnight esophageal pH may not be adequately sensitive. It is therefore possible that aggressive GERD therapy may improve asthma control in patients with “normal” overnight esophageal pH probe results. To our knowledge, there are no published data addressing this question.
Primary Objective The primary objective is to compare asthma control in asthmatic subjects treated with high dose PPI with asthmatic subjects taking placebo PPI. The primary outcome variables will be measurements of asthma symptoms and asthma quality of life.
Secondary Objectives Secondary objectives include evaluating the effect of this aggressive anti-secretory therapy on lung function, asthma medication use (including both baseline and rescue medication), and GERD symptoms. An additional secondary objective will be to evaluate whether the presence or absence of GERD symptoms at baseline (prior to proton pump inhibitor therapy) will independently associate with improvement in any of the other outcomes measured.
Measurements will include: Juniper Asthma Control Questionnaire (visits 2 and 5), Juniper Asthma Quality of Life Questionnaire (visits 2 - 5), GSAS gastroesophageal reflux instrument (visit 2, visit 5), the occurrence of adverse events, change in FVC, FEF25-75%, MIF50 / MEF50, peak expiratory flow rate, FEV1 reversibility, and the physical exam.
Additional measurements will include methacholine challenge and eosinophilia in induced sputum specimens. Induced sputum will be offered to all patients, though it is anticipated that only approximately 50% will agree to this procedure.
Ages Eligible for Study: | 18 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Washington | |
ASTHMA, Inc. | |
Seattle, Washington, United States, 98105 | |
ASTHMA, Inc. | |
Richland, Washington, United States, 99352 |
Principal Investigator: | Stephen A Tilles,, MD | ASTHMA, Inc. |
Study ID Numbers: | RAB-USA-38 |
Study First Received: | September 10, 2005 |
Last Updated: | September 19, 2005 |
ClinicalTrials.gov Identifier: | NCT00214552 |
Health Authority: | United States: Food and Drug Administration |
GERD Gastroesophageal reflux disease Asthma symptoms |
Esophageal disorder Gastrointestinal Diseases Asthma Gastroesophageal Reflux Esophageal Motility Disorders Deglutition Disorders Lung Diseases, Obstructive Hypersensitivity |
Digestive System Diseases Respiratory Tract Diseases Lung Diseases Hypersensitivity, Immediate Esophageal Diseases Rabeprazole Respiratory Hypersensitivity |
Molecular Mechanisms of Pharmacological Action Immune System Diseases Bronchial Diseases Therapeutic Uses |
Anti-Ulcer Agents Gastrointestinal Agents Enzyme Inhibitors Pharmacologic Actions |